{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:13:51Z","timestamp":1789010031042,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T00:00:00Z","timestamp":1509753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s12288-017-0901-1","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T08:06:47Z","timestamp":1509782807000},"page":"454-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["DA-EPOCH-R in Aggressive CD 20 Positive B Cell Lymphomas: Real-World Experience"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2762-6591","authenticated-orcid":false,"given":"Prasanth","family":"Ganesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trivadi S.","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshvardhan","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnarathinam","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manikandan","family":"Dhanushkodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanda Lucy Ann","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Sundersingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenali Gnana","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,4]]},"reference":[{"issue":"20","key":"901_CR1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","volume":"369","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C et al (2013) Low-intensity therapy in adults with Burkitt\u2019s lymphoma. N Engl J Med 369(20):1915\u20131925","journal-title":"N Engl J Med"},{"issue":"124","key":"901_CR2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V124.21.395.395","volume":"2014","author":"K Dunleavy","year":"2014","unstructured":"Dunleavy K, Fanale M, LaCasce A, Noy A, Caimi P, Parekh S et al (2014) Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma. Blood 2014(124):395","journal-title":"Blood"},{"issue":"15","key":"901_CR3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408\u20131416","journal-title":"N Engl J Med"},{"issue":"7","key":"901_CR4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O\u2019Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569\u20131580","journal-title":"Cancer"},{"issue":"12","key":"901_CR5","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/annonc\/mdt414","volume":"24","author":"AM Evens","year":"2013","unstructured":"Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N et al (2013) A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M\/IVAC regimen for untreated Burkitt\u2019s lymphoma. Ann Oncol 24(12):3076\u20133081","journal-title":"Ann Oncol"},{"issue":"15","key":"901_CR6","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","volume":"115","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF et al (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 115(15):3008\u20133016","journal-title":"Blood"},{"issue":"16","key":"901_CR7","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.26723","volume":"118","author":"SK Barta","year":"2012","unstructured":"Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA (2012) Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 118(16):3977\u20133983","journal-title":"Cancer"},{"issue":"37","key":"901_CR8","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32(27):3048\u201358","journal-title":"J Clin Oncol"},{"issue":"5","key":"901_CR9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"key":"901_CR10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood.V126.23.342.342","volume":"126","author":"K Dunleavy","year":"2015","unstructured":"Dunleavy K, Noy A, Abramson JS, LaCasce AS, Link BK, Parekh S et al (2015) Risk-adapted therapy in adults with Burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DA-EPOCH-R. Blood 126:342","journal-title":"Blood"},{"issue":"9","key":"901_CR11","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","volume":"119","author":"JM Ribera","year":"2013","unstructured":"Ribera JM, Garc\u00eda O, Grande C, Esteve J, Oriol A, Bergua J et al (2013) Dose-intensive chemotherapy including rituximab in Burkitt\u2019s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer 119(9):1660\u20131668","journal-title":"Cancer"},{"issue":"10","key":"901_CR12","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3109\/10428194.2013.878933","volume":"55","author":"B Xicoy","year":"2014","unstructured":"Xicoy B, Ribera JM, M\u00fcller M, Garc\u00eda O, Hoffmann C, Oriol A et al (2014) Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma\/leukemia: parallel study of 81 patients. Leuk Lymphoma 55(10):2341\u20132348","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"901_CR13","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","volume":"124","author":"D Hoelzer","year":"2014","unstructured":"Hoelzer D, Walewski J, D\u00f6hner H, Viardot A, Hiddemann W, Spiekermann K et al (2014) Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 124(26):3870\u20133879","journal-title":"Blood"},{"issue":"4","key":"901_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/0971-5851.95140","volume":"32","author":"M Sengar","year":"2011","unstructured":"Sengar M, Akhade A, Nair R, Menon H, Shet T, Gujral S et al (2011) A retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center. Indian J Med Paediatr Oncol 32(4):197\u2013203","journal-title":"Indian J Med Paediatr Oncol"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-017-0901-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-017-0901-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-017-0901-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T03:17:31Z","timestamp":1603250251000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-017-0901-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,4]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1007\/s12288-017-0901-1","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,4]]}}}